EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of the anti-pathogenic, genomic and phenotypic properties of a Lacticaseibacillus rhamnosus VHProbi M14 isolate

Jingyan Zhang iD, Kailing Li, Xinping Bu, Shumin Cheng, Zhi Duan iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285480 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Jingyan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Vland Biotech Inc, Nutrition & Health Technology Center, Qingdao, China. Hauptthemen laut MEDLINE: Lacticaseibacillus rhamnosus, Bacteriocins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Mountain Tai New Strategy Industry Leader Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A strain of lactic acid bacteria from cheese was isolated, that showed strong growth inhibitory effects on Streptococcus mutans . The API 50CH system and 16S rDNA sequencing verified that this was a novel strain, and was named Lacticaseibacillus rhamnosus VHProbi M14. The strain inhibited the growth of S . mutans and Fusobacterium nucleatum under mixed culture conditions, coaggregated with S . mutans and F . nucleatum , and reduced the adhesion of S . mutans and F . nucleatum on cultured human primary gingival epithelial (HPGE) cells. The pH, peroxidase and protease sensitivity testing found antibacterial substances of protein- and peptide-like structures in addition to organic acids. The antimicrobial substances were sensitive to hydrolysis with trypsin, papain and pineapple protease and were inactived at temperatures above 100°C. Ammonium sulphate-precipitated proteins from the M14 strain retained the ability to inhibit the growth of S . mutans and F . nucleatum . The M14 strain contained 23 bacteriocin-related genes encoding for metabolites, belonging to class II bacteriocins. The M14 strain also showed inhibitory effects on 8 other pathogenic strains ( A . actinomycetemcomitans , C . albicans , E . coli , G . vaginalis , P . acnes , P . gingivalis , S . aureus , S . enteritids ), and thus has a broad spectrum of bacterial inhibition. This new isolate has been identified as having potential to be used as a probiotic bacterium in clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacticaseibacillus rhamnosusBacteriocinsHumansLacticaseibacillusStaphylococcus aureusEscherichia coliStreptococcus mutansGenomics

Substanzen

Bacteriocins

Autor:innen und Institutionen

  • Qingdao Vland Biotech Inc, Nutrition & Health Technology Center, Qingdao, China.

ORCID-Profile: Jingyan Zhang, Zhi Duan

Förderung

  • the Mountain Tai New Strategy Industry Leader Program

Zitieren

APA

Zhang, J., Li, K., Bu, X., Cheng, S., & Duan, Z. (2023). Characterization of the anti-pathogenic, genomic and phenotypic properties of a Lacticaseibacillus rhamnosus VHProbi M14 isolate. PLOS ONE. https://doi.org/10.1371/journal.pone.0285480

Vancouver

Zhang J, Li K, Bu X, Cheng S, Duan Z. Characterization of the anti-pathogenic, genomic and phenotypic properties of a Lacticaseibacillus rhamnosus VHProbi M14 isolate. PLOS ONE. 2023. doi:10.1371/journal.pone.0285480

BibTeX
@article{Zhang2023,
  author = {Zhang, Jingyan and Li, Kailing and Bu, Xinping and Cheng, Shumin and Duan, Zhi},
  title = {Characterization of the anti-pathogenic, genomic and phenotypic properties of a Lacticaseibacillus rhamnosus VHProbi M14 isolate},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285480}
}
Kostenlos starten →